Three new cases of ataxia-telangiectasia-like disorder: No impairment of the ATM pathway, but S-phase checkpoint defect.


Journal

Human mutation
ISSN: 1098-1004
Titre abrégé: Hum Mutat
Pays: United States
ID NLM: 9215429

Informations de publication

Date de publication:
10 2019
Historique:
received: 07 09 2018
revised: 18 04 2019
accepted: 24 04 2019
pubmed: 30 4 2019
medline: 10 3 2020
entrez: 30 4 2019
Statut: ppublish

Résumé

Ataxia-telangiectasia-like disorder (ATLD) is a rare genomic instability syndrome caused by biallelic variants of MRE11 (meiotic recombination 11) characterized by progressive cerebellar ataxia and typical karyotype abnormalities. These symptoms are common to those of ataxia-telangiectasia, which is consistent with the key role of MRE11 in ataxia-telangiectasia mutated (ATM) activation after DNA double-strand breaks. Three unrelated French patients were referred with ataxia. Only one had typical karyotype abnormalities. Unreported biallelic MRE11 variants were found in these three cases. Interestingly, one variant (c.424G>A) was present in two cases and haplotype analysis strongly suggested a French founder variant. Variants c.544G>A and c.314+4_314+7del lead to splice defects. The level of MRE11 in lymphoblastoid cell lines was consistently and dramatically reduced. Functional consequences were evaluated on activation of the ATM pathway via phosphorylation of ATM targets (KAP1 and CHK2), but no consistent defect was observed. However, an S-phase checkpoint activation defect after camptothecin was observed in these patients with ATLD. In conclusion, we report the first three French ATLD patients and a French founder variant, and propose an S-phase checkpoint activation study to evaluate the pathogenicity of MRE11 variants.

Identifiants

pubmed: 31033087
doi: 10.1002/humu.23773
doi:

Substances chimiques

MRE11 protein, human 0
ATM protein, human EC 2.7.11.1
Ataxia Telangiectasia Mutated Proteins EC 2.7.11.1
MRE11 Homologue Protein EC 3.1.-

Types de publication

Case Reports Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1690-1699

Informations de copyright

© 2019 Wiley Periodicals, Inc.

Auteurs

Alice Fiévet (A)

Institut Curie, PSL Research University, Paris, France.
INSERM U830, D.R.U.M. team, Paris, France.
Institut Curie, Hôpital, Service de Génétique, Paris, France.

Dorine Bellanger (D)

Institut Curie, PSL Research University, Paris, France.
INSERM U830, D.R.U.M. team, Paris, France.

Stéphanie Valence (S)

APHP, GHUEP, Hôpital Armand Trousseau, Service de Neurologie Pédiatrique, Paris, France.
Centre de Référence Maladies Rares "Malformations et Maladies Congénitales du Cervelet", Paris-Lyon-Lille, France.
Sorbonne Université, GRC n°19, Pathologies Congénitales du Cervelet-LeucoDystrophies, APHP, Hôpital Armand Trousseau, Paris, France.
INSERM U1141, Université Paris Diderot, Paris, France.

Lenha Mobuchon (L)

Institut Curie, PSL Research University, Paris, France.
INSERM U830, D.R.U.M. team, Paris, France.

Alexandra Afenjar (A)

Centre de Référence Maladies Rares "Malformations et Maladies Congénitales du Cervelet", APHP, Hôpital Armand Trousseau, Paris, France.

Fabienne Giuliano (F)

Service de Génétique Médicale, CHU de Nice, Hôpital l'Archet 2, Nice, France.

Catherine Dubois d'Enghien (C)

Institut Curie, Hôpital, Service de Génétique, Paris, France.

Béatrice Parfait (B)

Centre de Ressources Biologiques, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France.

Jean-Michel Pedespan (JM)

Unité de Neuropédiatrie, CHU Pellegrin, Bordeaux, France.

Nathalie Auger (N)

Department of Biopathology, Gustave Roussy, Villejuif, France.

Guillaume Rieunier (G)

Institut Curie, PSL Research University, Paris, France.
INSERM U830, D.R.U.M. team, Paris, France.

Agnès Collet (A)

Institut Curie, Hôpital, Service de Génétique, Paris, France.

Lydie Burglen (L)

Centre de Référence Maladies Rares "Malformations et Maladies Congénitales du Cervelet", Paris-Lyon-Lille, France.
Sorbonne Université, GRC n°19, Pathologies Congénitales du Cervelet-LeucoDystrophies, APHP, Hôpital Armand Trousseau, Paris, France.
INSERM U1141, Université Paris Diderot, Paris, France.
Département de Génétique Médicale, APHP, GHUEP, Hôpital Armand Trousseau, Paris, France.

Dominique Stoppa-Lyonnet (D)

INSERM U830, D.R.U.M. team, Paris, France.
Institut Curie, Hôpital, Service de Génétique, Paris, France.
Faculté de Médecine, Université Paris-Descartes, Paris, France.

Marc-Henri Stern (MH)

Institut Curie, PSL Research University, Paris, France.
INSERM U830, D.R.U.M. team, Paris, France.
Institut Curie, Hôpital, Service de Génétique, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH